Neurogene Inc.
$26.14
+0.31%Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -4.8).
Valuation inputs: P/E -4.8, earnings yield N/A, momentum +0.3%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -34.1%, ROIC -37.5%).
Profitability stack: net margin 0.0%, ROE -34.1%, ROIC -37.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +8.2%, momentum +0.3%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Neurogene Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Neurogene Inc. Fair Value Envelope
Neurogene Inc. Profit Bridge
Profitability Analysis
Neurogene Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Neurogene Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Neurogene Inc. Street Expectations Map
Wall Street analysts project that NGNE stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 69.50, with estimates ranging from a low of 69.00 to a high of 70.00.
The consensus 1-year price target stands at 69.50, with estimates ranging from a low of 69.00 to a high of 70.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Neurogene Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.23M and sold $494K worth of NGNE shares, resulting in $735K of net buying activity.
3 Months
0
0.00
15.5K
373.24K
-373K
-$373K
3-6 Months
0
0.00
4.8K
120.53K
-121K
-$121K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
60.3K
1.23M
0
0.00
+1.2M
+$1.23M
Top Buyers
Baffi Robert
Director
$246K
Woods Robert Keith
Director
$246K
Palekar Rohan
Director
$246K
Freedland Cory S.
Director
$246K
Noonberg Sarah B.
Director
$246K
Top Sellers
Cvijic Christine Mikail
Director, Officer: President And Cfo
$320K
Cobb Stuart
Officer: Chief Scientific Officer
$81K
Mcminn Rachel
Director, Officer: Chief Executive Officer
$74K
Jordan Julie
Officer: Chief Medical Officer
$18K
Insider Activity Analysis
Net Insider Sentiment
Positive insider sentiment with $735K net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Buy/Sell Ratio
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 4 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
NGNE has not reported any dividend yield values in the available annual periods.
ngne Dividend History
Learning Layer
Related Guides
Build conviction on NGNE by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.